drugset
drugset / Trial / NCT03591146

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

NCT03591146 ↗

Phase 1/2 Completed 65 enrolled Taiwan Liposome Company
RandomizedSequentialQuadruple-blindSupportive care

Summary

Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin®

Timeline

Start
2018-07-31
Primary completion
2019-01-05
Completion
2019-01-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ropivacaine Other / unclassified 150 mg Other
Subject TLC590 Unknown 190 mg Other
Subject TLC590 Unknown 380 mg Other
Subject TLC590 Unknown 475 mg Other
Subject TLC590 Unknown 570 mg Other

Indications

No indication recorded.